|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.87 USD | -0.50% |
|
-5.13% | -2.67% |
| 03-06 | Corcept Therapeutics Insider Sold Shares Worth $296,346, According to a Recent SEC Filing | MT |
| 02-24 | Corcept Therapeutics Incorporated, Q4 2025 Earnings Call, Feb 24, 2026 |
| Capitalization | 3.6B 3.11B 2.8B 2.69B 4.91B 331B 5.13B 33.15B 13.28B 159B 13.52B 13.23B 568B | P/E ratio 2026 * |
88.2x | P/E ratio 2027 * | 21.1x |
|---|---|---|---|---|---|
| Enterprise value | 3.18B 2.74B 2.48B 2.38B 4.33B 292B 4.54B 29.28B 11.73B 140B 11.94B 11.69B 502B | EV / Sales 2026 * |
3.4x | EV / Sales 2027 * | 2.61x |
| Free-Float |
67.58% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Corcept Therapeutics Incorporated
| 1 day | -0.50% | ||
| 1 week | -5.13% | ||
| Current month | -5.13% | ||
| 1 month | -17.05% | ||
| 3 months | -60.66% | ||
| 6 months | -51.17% | ||
| Current year | -2.67% |
| 1 week | 32.99 |  | 36.27 |
| 1 month | 28.66 | | 41.92 |
| Current year | 28.66 | | 47.06 |
| 1 year | 28.66 | | 117.33 |
| 3 years | 20.45 | | 117.33 |
| 5 years | 15.82 | | 117.33 |
| 10 years | 3.85 | | 117.33 |
| Manager | Title | Age | Since |
|---|---|---|---|
Joseph Belanoff
CEO | Chief Executive Officer | 68 | 31/12/1998 |
Atabak Mokari
DFI | Director of Finance/CFO | 49 | 28/02/2021 |
Joseph Lyon
CTO | Chief Tech/Sci/R&D Officer | 48 | 31/01/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Joseph Belanoff
BRD | Director/Board Member | 68 | 31/12/1998 |
James Wilson
CHM | Chairman | 82 | 31/12/1998 |
David Mahoney
BRD | Director/Board Member | 71 | 30/06/2004 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +3.91% | 0.71% | 30 M€ | |
| +2.91% | 0.27% | 20 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.50% | -5.13% | -37.62% | +59.76% | 3.6B | |
| +0.72% | -5.86% | +8.50% | +210.49% | 885B | |
| +0.32% | -3.23% | +44.97% | +54.54% | 579B | |
| -0.96% | -0.85% | +9.19% | +48.19% | 407B | |
| -2.93% | -7.03% | +12.72% | +26.04% | 350B | |
| -1.25% | -5.55% | +23.92% | +55.59% | 302B | |
| -1.85% | -6.70% | +20.55% | +34.98% | 301B | |
| -0.24% | -6.49% | +23.18% | +4.22% | 286B | |
| +0.53% | -4.80% | +16.27% | +57.17% | 199B | |
| -0.83% | -3.37% | +24.03% | +77.45% | 179B | |
| Average | -0.70% | -4.71% | +14.57% | +62.84% | 349.23B | |
| Weighted average by Cap. | -0.47% | -4.59% | +19.82% | +86.06% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 935M 806M 728M 698M 1.27B 85.93B 1.33B 8.6B 3.45B 41.21B 3.51B 3.43B 147B | 1.19B 1.03B 930M 892M 1.63B 110B 1.7B 10.99B 4.4B 52.66B 4.48B 4.39B 188B |
| Net income | 40.28M 34.73M 31.35M 30.08M 54.86M 3.7B 57.41M 371M 148M 1.78B 151M 148M 6.35B | 221M 191M 172M 165M 302M 20.35B 316M 2.04B 816M 9.76B 831M 813M 34.9B |
| Net Debt | -420M -362M -327M -314M -572M -38.63B -599M -3.87B -1.55B -18.53B -1.58B -1.54B -66.25B | -479M -413M -373M -358M -652M -44.02B -683M -4.41B -1.77B -21.11B -1.8B -1.76B -75.51B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/03/26 | 33.87 $ | -0.50% | 1,230,034 |
| 05/03/26 | 34.04 $ | -4.62% | 1,330,893 |
| 04/03/26 | 35.69 $ | +1.16% | 1,082,134 |
| 03/03/26 | 35.28 $ | -1.92% | 1,397,589 |
| 02/03/26 | 35.97 $ | +0.76% | 1,134,415 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- CORT Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition